A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive BHV-4157 in Obsessive Compulsive Disorder
Phase of Trial: Phase II/III
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Trigriluzole (Primary)
- Indications Obsessive-compulsive disorders
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceutical
- 06 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the dosing for this trial was commenced in December 2017.
- 02 Jan 2018 Planned initiation date changed from 31 Dec 2017 to 19 Dec 2017.
- 14 Dec 2017 Status changed from not yet recruiting to recruiting.